Fig. 5.

Celecoxib modulates the increase in metabolites in the COX and LOX branches of the arachidonic acid cascade caused by CCl₄ treatment. (A–D) Hepatic tissue levels of metabolites in the COX branch. (E) Hepatic tissue levels of lipoxin A₄, a metabolite in the LOX branch. Tissue levels of compounds were analyzed by LC-MS/MS after solid-phase extraction as described in Materials and Methods. Mice were injected (intraperitoneally) with CCl₄ for 5 weeks. The inhibitors were administered subcutaneously via osmotic minipumps that delivered the compounds at a calculated dose of 10 mg/kg per day for a 30-g mouse. For a simplified diagram of these pathways, see Supplemental Fig. S1. Error bars represent S.D. *P value vs. control group <0.05. ^‡P value vs. CCl₄ only group <0.05. ^#P value vs. celecoxib + CCl₄ group <0.05. n = 6 for celecoxib + CCl₄ group, n = 5 for all other groups. Statistical tests are described in Materials and Methods. The raw data used for this figure are reported in Supplemental Table S3.